<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303758</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000453841</org_study_id>
    <secondary_id>FFCD-0301</secondary_id>
    <secondary_id>EU-20543</secondary_id>
    <nct_id>NCT00303758</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, cisplatin, and
      gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
      and giving them in different ways may kill more tumor cells. It is not yet known which
      combination chemotherapy regimen is more effective in treating metastatic pancreatic cancer.

      PURPOSE: This randomized phase III trial is studying two different combination chemotherapy
      regimens to compare how well they work in treating patients with metastatic pancreatic cancer
      that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the overall survival of patients with unresectable metastatic pancreatic cancer
           treated with fluorouracil, leucovorin calcium, and cisplatin followed by gemcitabine
           hydrochloride vs gemcitabine hydrochloride followed by fluorouracil, leucovorin calcium,
           and cisplatin.

      Secondary

        -  Compare progression-free survival of patients treated with these regimens.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the quality of life of patients treated with these regimens.

        -  Compare the percentage of these patients needing second-line therapy.

        -  Compare the duration of hospitalization of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG
      performance status (0 or 1 vs 2), participating center, location of the tumor (ampullar
      region vs other locations), and infusion rate of gemcitabine hydrochloride (30 vs 100
      minutes). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive leucovorin calcium IV over 2 hours on day 1, cisplatin IV over 1
           hour on day 1 or 2, and fluorouracil IV over 46 hours on day 1 and 2. Treatment repeats
           every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients
           with disease progression also receive gemcitabine hydrochloride IV over 30 or 100
           minutes weekly for 7 weeks. Patients then receive gemcitabine hydrochloride IV on days
           1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or
           unacceptable toxicity.

        -  Arm II: Patients receive gemcitabine hydrochloride IV over 30 or 100 minutes weekly for
           7 weeks in the absence of disease progression or unacceptable toxicity. Patients with
           disease progression receive fluorouracil, leucovorin calcium, and cisplatin as in arm I.

      Quality of life is assessed at baseline and then every 2 months.

      After completion of study therapy, patients are followed periodically for 2 years.

      PROJECTED ACCRUAL: A total of 202 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients needing second-line therapy</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>LV5FU2 simplifié + cisplatine puis gemcitabine si progression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LV5FU2 simplifié + cisplatine puis gemcitabine si progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemcitabine puis LV5FU2 simplifié + cisplatine si progression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine puis LV5FU2 simplifié + cisplatine si progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>LV5FU2 simplifié + cisplatine puis gemcitabine si progression</arm_group_label>
    <arm_group_label>gemcitabine puis LV5FU2 simplifié + cisplatine si progression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>LV5FU2 simplifié + cisplatine puis gemcitabine si progression</arm_group_label>
    <arm_group_label>gemcitabine puis LV5FU2 simplifié + cisplatine si progression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>LV5FU2 simplifié + cisplatine puis gemcitabine si progression</arm_group_label>
    <arm_group_label>gemcitabine puis LV5FU2 simplifié + cisplatine si progression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>LV5FU2 simplifié + cisplatine puis gemcitabine si progression</arm_group_label>
    <arm_group_label>gemcitabine puis LV5FU2 simplifié + cisplatine si progression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas or ampulla

               -  Metastatic disease

               -  Unresectable disease

          -  Measurable disease, meeting the following criteria:

               -  No prior radiotherapy to the only site of measurable disease

               -  Diameter &gt; 10 mm by spiral CT scan or MRI OR &gt; 20 mm by conventional methods

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 2 months

          -  No contraindication to chemotherapy

          -  Creatinine clearance &gt; 60 mL/min

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Alkaline phosphatase &lt; 5 times normal

          -  Bilirubin ≤ 3 mg/dL

          -  No coronary insufficiency

          -  No symptomatic cardiac disease

          -  Good hydration possible

          -  No Child-Pugh class B or C cirrhosis

          -  No other malignancy except for basal cell skin cancer or carcinoma in situ of the
             cervix

          -  Not pregnant or nursing

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior palliative or adjuvant chemotherapy

          -  At least 4 weeks since prior radiotherapy

          -  No radiotherapy during or for 4 weeks after study therapy

          -  No other concurrent anticancer therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Seitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de la Timone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Louis Legoux, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Haut Leveque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Hammel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Beaujon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier d'Abbeville</name>
      <address>
        <city>Abbeville</city>
        <zip>80101</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Blois</name>
      <address>
        <city>Blois</city>
        <zip>41016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Docteur Duchenne</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Ambroise Pare - Boulogne</name>
      <address>
        <city>Boulogne</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Bourg En Bresse</name>
      <address>
        <city>Bourg En Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Pierre Oudot</name>
      <address>
        <city>Bourgoin-Jallieu</city>
        <zip>38300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Amiens</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chalons-en-Champagne</name>
      <address>
        <city>Chalons-en-Champagne</city>
        <zip>51000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Clermont Ferrand, Hotel dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Draguignan</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Dunkerque - CHD</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal St. Aubin les Elbeuf</name>
      <address>
        <city>Elbeuf</city>
        <zip>76503</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital de la Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Guilherand Granges</city>
        <zip>07500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional et Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Martigues</name>
      <address>
        <city>Martigues</city>
        <zip>13698</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General de Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Ste - Marie</name>
      <address>
        <city>Pontoise</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Joliot Curie Des Docteurs Jean-Christophe Chardon Jacques Hernandez Et Laurent Gasnault</name>
      <address>
        <city>Saint Martin Boulogne</city>
        <zip>62280</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint-Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Semur en Auxois</name>
      <address>
        <city>Semur en Auxois</city>
        <zip>21140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Soissons</name>
      <address>
        <city>Soissons cedex</city>
        <zip>02209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tarbes</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvelle Clinique Generale</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010 Nov;59(11):1527-34. doi: 10.1136/gut.2010.216135.</citation>
    <PMID>20947887</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitry E, Dahan L, Ychou M, et al.: LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: preliminary results of a randomized phase III trial (FFCD 0301). [Abstract] J Clin Oncol 26 (Suppl 15): A-4513, 2008.</citation>
  </results_reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

